Trends in Pharmacological Sciences
ReviewSerotonin research: contributions to understanding psychoses
Introduction
The history of research on serotonin, or 5-hydroxytryptamine (5-HT), is closely intertwined with modern studies of the neurobiological origins of psychotic states in general and the group of schizophrenia disorders in particular. Among the defining events that led to this early association were the discoveries of the psychosis-like effects of lysergic acid diethylamide (LSD) by the late Albert Hofmann (Sandoz, www.sandoz.com) and the identification, less than a decade later, of serotonin as an endogenous neurohormone. As summarized in Table 1, the concept that the drug-induced psychotic state induced by LSD is attributable to either antagonist or agonist actions at serotonin receptors rapidly led to the suggestion that LSD provides a model psychosis. This concept prompted the fundamental hypotheses that abnormalities of serotonin function are responsible for psychiatric disorders such as the spectrum of schizophrenia disorders and, therefore, that serotonin agonists or antagonists might be useful in the treatment of schizophrenia. Experimental studies have confirmed early descriptions [1] of striking similarities between psychotic states in psychiatric disorders and the subjective reports of subjects under the influence of psychedelic drugs. Serotonergic hallucinogens such as LSD or the naturally occurring compound psilocybin produce profound changes in mood, thought, intuition, sensory perception, the experience of time and space, and even the experience of self. In these states, perceptual hypersensitivity, illusions and elementary hallucinations are common. In general, the intensity of these alterations of perception and consciousness are dose dependent, so that hallucinations involving disorientation in person, place and time rarely, if ever, occur with low-to-medium doses 2, 3. Depending upon the individual, the individual's expectations and the setting, the same hallucinogen might produce a loss of ego boundaries combined with elevated mood states ranging from pleasure to bliss and feelings of oneness, or might lead to more psychotic ego dissolution including fear and paranoid ideation associated with experiences of split ego [4]. Such experiential phenomena are otherwise rarely reported except in dreams, contemplative or religious exaltation, and acute psychoses 5, 6, 7. Thus, the discovery of the effects of LSD led rapidly to the suggestion that serotonergic hallucinogens provide model psychoses and, more generally, to the serotonin hypothesis of schizophrenia. The subsequent experimental assessment of these hypotheses and the new directions of research engendered by this line of work are discussed here.
Section snippets
Parallels between dose-related hallucinogen effects and the development of schizophrenia
Systematic comparisons of the symptom profiles associated with serotonergic hallucinogens and schizophrenia disorders have demonstrated robust qualitative similarities with the earliest phases of schizophrenic psychoses, with fewer similarities being evident in the chronic phases of the illnesses 8, 9, 10, 11, 12. The heightened awareness and euphoria reported by some healthy volunteers treated with psilocybin or the phenalkylamine hallucinogen mescaline in addition to the negative affective
Experimental studies of the model psychosis induced by serotonin agonists
A commonality among many theoretical descriptions of the neuronal basis of the symptomatology in schizophrenia and other psychotic disorders is the basic idea that deficits in early information processing engender the cognitive disturbances and even the psychotic symptoms observed in psychotic disorders in psychiatry 18, 19, 20. The notion is that an underlying dysfunction of information-processing mechanisms in the schizophrenia spectrum involves an inability of these patients to screen out,
Serotonin receptors involved in psychotomimetic effects
The initial uncertainty in the mid-1950s (Table 1) as to whether serotonergic hallucinogens such as LSD or psilocybin function primarily as serotonin agonists or antagonists 39, 40 continued well through the 1980s. As reviewed in Ref. [15], studies using different model systems indicated that LSD is an agonist, a partial agonist or even an antagonist at serotonin receptors. Suffice it to say that the accumulated evidence from biochemical, electrophysiological and behavioral studies in animals
Serotonin circuits and interactions with other systems
Early research into the effects of serotonergic hallucinogens and hallucinogenic anesthetics (e.g. phencyclidine and ketamine) on brain electrical activity in animals indicated that the key psychological effects of these drugs arise along a continuum of excitation. Specifically, after an initial excitation characterized by electro-encephalographic (EEG) desynchronization and psychomotor activation, all of these drugs induce a state with intermittent bursts of hypersynchronous 2.5-Hz EEG wave
New directions for research on serotonin and psychosis
Despite the extensive research linking serotonin and psychosis over the past six decades, exciting new findings are now prompting studies of novel mechanisms that could further our understanding of the neurobiology of drug- and disease-induced psychoses. Experimental approaches ranging from molecular biology to behavioral studies indicate that the unifying principle of 5-HT2A-agonist actions as mediating the psychedelic and psychotomimetic effects of serotonergic hallucinogens is
Future research on serotonergic contributions to psychoses
Six decades of discovery, observation and experimental study have generated compelling evidence that serotonergic systems and particularly central 5-HT2A receptors are important in the genesis of drug-induced psychotic states and in the treatment and potentially the etiology of some psychotic disorders such as schizophrenia. The chemical tools of discovery provided by the late Albert Hofmann facilitated the elucidation of this fundamental relationship between serotonin and psychosis. Research
Acknowledgements
We dedicate this work to the memory of Albert Hofmann, who passed away at the age of 102 during the preparation of this review. He was a friend and inspiration to both these and many other authors. M.A.G. was supported by the National Institute on Drug Abuse (DA02925) and the Veterans Affairs VISN 22 Mental Illness Research, Education and Clinical Center. F.X.V. was supported by the Swiss National Science Foundation, Swiss Federal Office of Health (BAG), the National Alliance for Research on
References (60)
- et al.
Mescaline, lysergic acid diethylamid and psilocybin: comparison of clinical syndromes, effects on color perception and biochemical measures
Comparative Psychiatry
(1962) Hallucinogenic drug induced states resemble acute endogenous psychoses: results of an empirical study
Eur. Psychiatry
(1998)Hallucinogens
Pharmacol. Ther.
(2004)- et al.
A systems model of altered consciousness: integrating natural and drug-induced psychoses
Brain Res. Bull.
(2001) Deficits in prepulse inhibition and habituation in never-medicated first-episode schizophrenia
Biol. Psychiatry
(2003)Serotonergic basis of antipsychotic drug effects in schizophrenia
Biol. Psychiatry
(1998)The role of serotonin in antipsychotic drug action
Neuropsychopharmacology
(1999)Correlation of positive symptoms exclusively to hyperperfusion or hypoperfusion of cerebral cortex in never-treated schizophrenics
Lancet
(1997)Sensorimotor gating of schizophrenia patients is influenced by 5-HT2A receptor polymorphisms
Biol. Psychiatry
(2008)- et al.
Serotonin and hallucinogens
Neuropsychopharmacology
(1999)
Neurometabolic effects of psilocybin, 3,4-methylenedioxyethylamphetamine (MDE) and d-methamphetamine in healthy volunteers. A double-blind, placebo-controlled PET study with [18F]FDG
Neuropsychopharmacology
DOI disrupts prepulse inhibition of startle in rats via 5-HT2A receptors in the ventral pallidum
Brain Res.
Hallucinogens recruit specific cortical 5-HT2A receptor-mediated signaling pathways to affect behavior
Neuron
Serum vasoconstrictor, serotonin; chemical inactivation
J. Biol. Chem.
Lysergsäure-diäthylamid, ein Phantastikum aus der Mutterkorngruppe
Schweiz. Arch. Neurol. Psychiat
Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study
Psychopharmacology (Berl.)
The standardized psychometric assessment of altered states of consciousness (ASCs) in humans
Pharmacopsychiatry
A cartography of the ecstatic and meditative states
Science
Psychotomimetic agents
The Neuropharmacology of religious experience: hallucinogens and the experience of the divine
“Psychedelic” experiences in acute psychoses
Arch. Gen. Psychiatry
The early symptoms of schizophrenia
Br. J. Psychiatry
History, rationale and potential of human experimental hallucinogen drug research in psychiatry
Pharmacopsychiatry
Similarity of schizophrenia and the psilocybin syndrome as determined by objective methods
Int. J. Neuropsychiatry
Blood flow and cerebral laterality in the mescaline model of psychosis
Pharmacopsychiatry
Brain mechanisms of hallucinogens and entactogens
Dialogues Clin. Neurosci.
Early subjective experiences in schizophrenic episodes
J. Abnorm. Psychol.
Symptom differences in schizophrenia with good and poor prognosis
Am. J. Psychiatry
Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies
Psychopharmacology (Berl.)
Startle habituation and sensorimotor gating in schizophrenia and related animal models
Schizophr. Bull.
Cited by (332)
A Brief Historical Overview of Psychedelic Research
2024, Biological Psychiatry: Cognitive Neuroscience and NeuroimagingPrimary states of consciousness: A review of historical and contemporary developments
2023, Consciousness and CognitionToward Mapping Neurobehavioral Heterogeneity of Psychedelic Neurobiology in Humans
2023, Biological PsychiatryThe crosstalk between 5-HT<inf>2A</inf>R and mGluR2 in schizophrenia
2023, Neuropharmacology